Indoco Remedies Ltd (INDOCO) — shareholding pattern, promoter holding, financials and share price
About Indoco Remedies Ltd (INDOCO)
Indoco Remedies Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as INDOCO and on the BSE under scrip code 532612. Its ISIN is INE873D01024.
Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). [1]
Indoco Remedies Limited is a Mumbai-based pharmaceutical company engaged in manufacturing and marketing pharmaceutical formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).
The company has showcased strong performance in its exports division, especially in emerging markets and its subsidiaries like FPP in the U.S. and Warren Remedies, with a notable increase in OTC business.
Listed peers in Pharmaceuticals: Solara Active Pharma Sciences Ltd, Kwality Pharmaceuticals Ltd, Sai Parenterals Ltd, Beta Drugs Ltd, Venus Remedies Ltd, Ind-Swift Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹261.2 a share on 10 Jul 2026, Indoco Remedies Ltd (INDOCO) was valued at a price-to-book of 2.36x on a book value of ₹110.72 per share as of Mar 2025. Solomo computes return on equity of -9.66% and return on capital employed of 0.78% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- Industry P/E
- 36.41x
- P/B
- 2.36x
- EPS (TTM)
- ₹-10.69
- Book value / share
- ₹110.72
- ROE
- -9.66%
- ROCE
- 0.78%
- ROA
- -4.06%
- Debt / equity
- 0.97x
- Dividend yield
- 0.08%
- EBITDA margin
- 7.93%
- 52-week range
- ₹163.7 – ₹348.1
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Indoco Remedies Ltd (INDOCO) reported revenue of ₹1,845 crore, net profit of ₹-99 crore and earnings per share of ₹-10.31. That compares with revenue of ₹1,665 crore and net profit of ₹-78 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹476 crore and net profit ₹-24 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,541 | 1,669 | 1,817 | 1,665 | 1,845 |
| Net profit (₹ cr) | 155 | 142 | 97 | -78 | -99 |
| EPS (₹) | 16.8 | 15.44 | 10.68 | -7.99 | -10.31 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 4.69% | 6.54% | -0.47% | -8.38% |
| Profit growth | - | - | - | -180.36% |
| Stock price CAGR | -2% | -11% | -9% | -26% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 58.86% of Indoco Remedies Ltd (INDOCO) (unchanged from the previous quarter), foreign institutional investors (FII) hold 1.27% and domestic institutional investors (DII) hold 17.68%. Market capitalisation was ₹2,411 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2005.
Largest disclosed public shareholders in Jun 2026: NIPPON LIFE INDIA TRUSTEE LTD A/C NIPPON INDIA SMALL CAP FUND 4.8%, QUANT MUTUAL FUND QUANT SMALL CAP FUND 4.55%, DSP HEALTHCARE FUND 4.34%, ICICI PRUDENTIAL PHARMA HEALTHCARE AND DIAGANOSTICS (P.H.D.) FUND 1.8%, HDFC VALUE FUND 1.66%, MANGESHI INVESTMENT PRIVATE LIMITED 1.26%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 58.86% | - | 1.27% | 17.68% | 41% |
| Mar 2026 | 58.86% | - | 0.94% | 18.15% | 41% |
| Dec 2025 | 58.9% | - | 1.1% | 18.15% | 41.01% |
| Sep 2025 | 58.9% | - | 1.25% | 18.16% | 41.01% |
| Jun 2025 | 58.9% | - | 1.22% | 18.96% | 41.01% |
| Mar 2025 | 58.9% | - | 1.24% | 18.75% | 41.01% |
| Dec 2024 | 58.8% | - | 1.25% | 18.9% | 41.17% |
| Sep 2024 | 58.75% | - | 1.7% | 18.24% | 41.21% |